Hong Kong Life Sciences Stock News

SEHK:8
SEHK:8Telecom

How Investors Are Reacting To PCCW (SEHK:8) Expanding Its FWD Branding And Marketing Partnership

In December 2025, PCCW Interactive Media Holdings Limited, a subsidiary of PCCW, entered into a Branding and Marketing Arrangements Framework Agreement with FWD Life Insurance covering 1 January 2026 to 31 December 2028, under which PCCW Group (including the HKT Group) will provide branding, spokesperson and marketing services charged at market-referenced rates. The agreement is grounded in arm’s length annual caps informed by historical IFRS-recognised service revenues of about US$6.60...
SEHK:9966
SEHK:9966Biotechs

Is Alphamab Oncology (SEHK:9966) Quietly Reframing Its Immuno-Oncology Edge With JSKN033’s Phase II IND?

In late 2025, Alphamab Oncology’s board announced that China’s Center for Drug Evaluation had accepted its Investigational New Drug application for a phase II trial of JSKN033, a high-concentration subcutaneous co-formulation combining a HER2-targeting bispecific ADC and a PD-L1 inhibitor with platinum-based chemotherapy, with or without bevacizumab, in advanced cervical cancer. This acceptance marks a key progression in Alphamab Oncology’s immuno-oncology pipeline, highlighting its effort...